The Food and Drug Administration included U.S. Patent No. 7,635,773 in the Orange Book listing for NEXTERONE®

Prism Pharmaceuticals’ Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology

First Time IV Formulation of Clopidogrel, the Active Ingredient in Plavix® (clopidogrel bisulfate), Is Studied in Humans

KING OF PRUSSIA, Pa., February 9, 2009. Prism Pharmaceuticals announced today that the results of the first-in-man study of PM103, a novel intravenous formulation of clopidogrel bisulfate (the active ingredient in PLAVIX), has been accepted for poster presentation at the 58th Scientific Session of the American College of Cardiology (ACC) on March 30, 2009. The poster will be presented at the ACC's Innovation in Intervention: i2 Summit 2009 in partnership with the Cardiovascular Research Foundation...more>

Prism Pharmaceuticals Receives FDA Approval of NEXTERONE for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia

Novel Formulation Addresses Limitations of Amiodarone IV

KING OF PRUSSIA, Pa., January 5, 2009. Prism Pharmaceuticals announced today that the US Food & Drug Administration (FDA) has approved the new drug application (NDA) for NEXTERONE® (amiodarone HCl) Injection, a novel, patent-protected, cosolvent-free formulation of the antiarrhythmic agent Amiodarone IV, originally marketed in the US by Wyeth as Cordarone® Intravenous. NEXTERONE is indicated for the treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy...more>

Prism Pharmaceuticals to Receive $10 Million Milestone Payment from Paul Capital Healthcare

KING OF PRUSSIA, Pa., January 8, 2009. Prism Pharmaceuticals, Inc. announced today that it will receive a $10 million milestone payment from Paul Capital Healthcare (formerly Paul Royalty Funds), the healthcare investment platform of Paul Capital. The milestone payment is triggered by the recent US Food and Drug Administration (FDA) approval of the new drug application (NDA) for NEXTERONE® (amiodarone HCl) Injection, a novel, patent-protected, cosolvent-free formulation of the antiarrhythmic agent Amiodarone IV. The long-range financing agreement with Paul Capital Healthcare, established in September 2006, provides Prism with non-dilutive capital to bring NEXTERONE through to commercial launch in the US...more>

BIO-Europe Spring 2009

March 16–18, 2009. Prism Pharmaceuticals has been invited to present at this year’s BIO-Europe Spring 2009 Conference to be held at the Milano Convention Center in Milan, Italy. Prism is presenting at this event to share corporate plans and explore partnering opportunities for NEXTERONE throughout Europe. Parties interested in scheduling a one-on-one meeting with Prism at this event should contact the company through the BIO-Europe Spring 2009 website: http://www.ebdgroup.com/bes/partnering.htm.